Hospital stewardship is moving from retrospective review to near real-time action
Hospital stewardship programs are being recast as operational tools for both patient safety and cost control. In a MedCity News webinar tied to Pharmacy Week 2026, pharmacy leaders will discuss how antibiotic stewardship and opioid stewardship are converging around a shared goal: tighter oversight, faster intervention, and less manual review for already stretched pharmacy teams. The discussion is sponsored by Inovalon and centers on a shift from retrospective dashboards to near real-time surveillance with risk prioritization and closed-loop intervention.
The framing reflects a practical reality inside health systems. Stewardship is no longer confined to reviewing prescribing patterns after the fact. Hospitals are being asked to monitor risk as it emerges, decide which cases require immediate attention, and direct pharmacist effort toward the patients most likely to benefit from intervention. In that model, stewardship becomes less of an audit function and more of a clinical operations layer embedded in daily care.
One blunt truth sits beneath the webinar topic: delayed stewardship is expensive.
Surveillance now drives stewardship decisions before waste accumulates
Among the core themes is the move toward near real-time surveillance. In a hospital environment, that means tracking prescribing activity and patient-level factors closely enough to act before an antibiotic course drifts too long, before an opioid regimen becomes excessive, or before a high-risk medication pattern hardens into avoidable harm. The article identifies type of infection, risk factors, and duration of therapy as among the factors providers weigh when considering antibiotics and opioids. Those variables matter because they shape whether a drug is necessary, whether the dose is appropriate, and whether the duration fits the clinical indication.
This matters clinically because stewardship failures usually do not arrive as a single dramatic event. They accumulate through marginal decisions: an antibiotic that remains on the chart after cultures return, an opioid order that persists after pain begins to improve, or a high-acuity patient whose risk profile goes unnoticed until the chart is manually reviewed. Near real-time systems aim to interrupt those patterns earlier. The promise is not abstract efficiency; it is the ability to reduce unnecessary exposure, preserve antimicrobial utility, and limit avoidable adverse effects tied to strong medications.
Smart risk prioritization is designed to narrow the pharmacist’s workload
The webinar will also address smart risk prioritization and closed-loop intervention. In practice, that combination means systems identify which cases are most urgent, route them to the right pharmacist, and support follow-through after the recommendation is made. Closed-loop workflows are especially important because stewardship recommendations only matter if they are seen, accepted, and acted on in a timely way. Without a feedback loop, even well-designed alerts become noise.
Martha Tran, Pharm.D., Senior Director of Customer Operations at Inovalon, and Josh Caraccio, Pharm.D., BCPS, BCIDP, Principal Implementation Engineer at Inovalon, are slated to participate, with MedCity News Editor-in-Chief Arundhati Parmar moderating. The lineup signals a discussion that blends clinical pharmacy practice with implementation strategy. Pharmacists are being positioned to work at the top of their license, a phrase that in this context means shifting their time away from broad manual chart review and toward direct, high-value clinical decision-making.
The operational logic is easy to grasp. If an algorithm can filter routine cases and surface only the most consequential ones, pharmacists can focus on patients with the highest likelihood of benefit from intervention. In a hospital under cost pressure, that kind of triage is not simply administrative convenience. It is how stewardship programs become scalable rather than dependent on ever-expanding manual labor.
Antibiotic and opioid stewardship share the same control points
Although antibiotics and opioids are often discussed in separate silos, the webinar presents them as governed by the same stewardship playbook. Both depend on surveillance, prioritization, and intervention workflows. Both can consume substantial clinical time when review is entirely manual. Both can lead to harm when overused, continued too long, or selected without adequate attention to the underlying indication.
The overlap is more than a workflow convenience. Antibiotic stewardship is tied to resistance, collateral toxicity, and the consequences of unnecessary exposure. Opioid stewardship is tied to the risks of oversedation, dependence, and inappropriate continuation after the acute need has passed. In both cases, the hospital must balance immediate symptom control with long-term safety and system-wide sustainability. A stewardship platform that can manage both medication classes through a common infrastructure may reduce duplication and lower the burden on pharmacists who otherwise have to navigate separate review processes for drugs with very different clinical use patterns.
Cost containment depends on better medication governance, not just tighter budgets
The webinar is being positioned as part of a broader conversation about hospital cost containment and long-term sustainability. That angle is clinically relevant because medication waste is rarely just a finance issue. Excess drug exposure can prolong recovery, generate complications, and create downstream utilization that erases any short-term savings from loose prescribing. Stewardship programs that reduce unnecessary use can therefore support both financial health and patient outcomes at the same time.
Still, the value proposition depends on execution. Near real-time surveillance only helps if the underlying data are accurate, the risk stratification is trustworthy, and the intervention pathway is fast enough to change prescribing behavior while the decision still matters. Hospitals considering these tools will have to judge not only whether the technology detects patterns, but whether it meaningfully changes what pharmacists and clinicians do at the bedside.
The more exacting test is whether the workflow reduces manual burden without dulling clinical judgment. Stewardship succeeds when it protects patients from avoidable medication harm and gives pharmacists a sharper, more sustainable role in hospital care. If the system simply produces more alerts without better action, the burden shifts rather than improves.